Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03072485 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers
A Phase 1 study of Aging, sponsored by Anne Chang.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03072485: Completed Phase 1 study of Aging, sponsored by Anne Chang.
NCT03072485 is a Phase 1 study of Aging that has completed, run by Anne Chang. The registered enrollment target is 10 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03072485, a Phase 1 study of Aging, has completed, sponsored by Anne Chang.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1 study in healthy adult volunteers to examine the effects of 3 FDA approved medications on skin aging when applied in topical form. This is an open label, placebo controlled study.
Primary Outcome
Profile of gene transcript changes
Conditions Studied
Interventions
- DRUG Sirolimus
- DRUG Metformin
- DRUG Diclofenac
Study Locations (1)
California
- Stanford Dermatology - Redwood City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2019-02-22 |
| Phase | Phase 1 |
What the finished NCT03072485 record still lists
NCT03072485 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Aging appearing as the primary indexed condition, and to 3 interventions - of which Sirolimus is the first listed.
NCT03072485 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03072485 about?
NCT03072485 is a clinical study titled "Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers". This is a phase 1 study in healthy adult volunteers to examine the effects of 3 FDA approved medications on skin aging when applied in topical form. This is an open label, placebo controlled study.
What is the current status of trial NCT03072485?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2017-03-01. Estimated completion is 2019-02-22.
What conditions does trial NCT03072485 study?
This clinical trial studies the following conditions: Aging.
What interventions are being tested in trial NCT03072485?
The interventions under investigation include: Sirolimus (DRUG), Metformin (DRUG), Diclofenac (DRUG).
Who is sponsoring clinical trial NCT03072485?
This trial is sponsored by Anne Chang, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03072485 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03072485's enrollment target sits among peer trials
10 258th of 262 higher than 2 of 262 other Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of a Daily Supplement on Plasma PAI-1 Levels
RECRUITING · Phase 1
-
MTOR Inhibitors in Older Adults
RECRUITING · Phase 1
-
Rapalog Pharmacology (RAP PAC) Study
RECRUITING · Phase 1
-
Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults
RECRUITING · Phase 1
-
Fisetin to Improve Vascular Function in Older Adults
ACTIVE NOT RECRUITING · Phase 1
-
Wild Blueberries and Cardiovascular Health in Middle-aged/Older Men and Postmenopausal Women
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI